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ABSTRACT
Tumor necrosis factor a (TNF-a) promotes bone loss and inhibits bone formation. Osterix (Osx, SP7) is a transcription factor required for
osteoblast (OB) differentiation because deletion results in a cartilaginous skeleton. We previously described a TNF suppressor element in
the Osx promoter that was used to isolate nuclear proteins mediating TNF inhibition of OB differentiation. Nuclear extracts from TNF-
treated pre-OBs were incubated with the TNF suppressor element for protein pull-down, and tryptic fragments were analyzed by mass
spectrometry. Chromatin immunoprecipitation (ChIP) assay confirmed eight bound transcription factors. One protein, the paired related
homeobox protein (Prx1), had been shown previously to have a critical role in limb bud formation and skeletal patterning. PCR revealed
Prx1 expression in primary stromal cells (MSCs), C3H10T1/2 cells, and MC3T3 preosteoblasts. TNF stimulated a 14-fold increase in mRNA
forPrx1,rapidcellaccumulationinMC3T3cells,andexpressioninperiostealandtrabecularliningcellsinvivo.TransientexpressionofPrx
inhibited transcription of Osx and RUNX2. Expression of the Prx1b isoform or Prx2 decreased Osx and RUNX2 mRNA and OB
differentiation in preosteoblasts. Silencing of Prx1 with siRNA abrogated TNF suppression of Osx mRNA and increased basal Osx
expression. Electrophoretic mobility shift revealed Prx1b as the preferred isoform binding the Osx promoter. These results identify the
homeobox protein Prx1 as an obligate mediator of TNF inhibition of Osx and differentiation of OB progenitors. Activation of Prx1 by TNF
may contribute to reduced bone formation in inflammatory arthritis, menopause, and aging.  2011 American Society for Bone and
Mineral Research.
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Introduction
O
steoblasts are derived from pluripotent precursors of
mesenchymal lineage. In adult bone, fracture healing and
renewal recapitulate the developmental steps of bone forma-
tion, including recruitment and differentiation of new bone-
forming osteoblasts (OBs).
(1) OBs first must proliferate from a
pluripotent precursor pool and then differentiate along a path
toward a mature bone-forming phenotype rather than one of an
adipocyte, myoblast, or fibroblast. Each step in the precursor
commitment of an OB is orchestrated by expression of skeletal-
specific transcription factors.
(2–5) Critical transcription factors for
OB differentiation include the runt-related factor (RUNX2, Cbfa1,
AML3, and Pebp2aA2) and osterix (Osx, Sp7) because early
knockout of these genes results in a cartilaginous skeleton.
(6–10)
The expression of RUNX2 and Osx is under regulation of soluble
growth factors, cytokines, and systemic hormones. Several
studies have shown a continued requirement for expression of
skeletal transcription factors in adult bone.
(11) We, and others,
have hypothesized that inhibition of the expression of RUNX2
or Osx in inflammatory arthritis may impair bone formation
and predispose to increased periarticular and systemic bone
loss.
(12–20)
Tumor necrosis factor a (TNF-a) has an important role as a
mediator of skeletal damage in inflammatory arthritis.
(14,21,22)
TNF-a is now well established as a stimulus for the early
ORIGINAL ARTICLE J JBMR
Received in original form October 26, 2009; revised form June 19, 2010; accepted July 22, 2010. Published online August 3, 2010.
Address correspondence to: Mark S Nanes, MD, PhD, Chief of Medicine, Mail Code 111, VA Medical Center, 1670 Clairmont Road, Decatur, GA 30033, USA.
E-mail: mnanes@emory.edu
Journal of Bone and Mineral Research, Vol. 26, No. 1, January 2011, pp 209–219
DOI: 10.1002/jbmr.203
 2011 American Society for Bone and Mineral Research
209recruitment of preosteoclasts from marrow progenitors and for
expression of the receptor activator of NF-kB ligand (RANKL)
and monocyte colony-stimulating factor (M-CSF) for subsequent
genesis of bone-resorbing osteoclasts. In rheumatoid arthritis,
TNF-a reaches high concentrations in the joint space during
active disease, where it contributes to extensive tissue destruc-
tion.
(23) A lower level of monocyte-derived TNF-a percolates in
the bloodstream and contributes to systemic osteoporosis and
increased fracture risk in inflammatory arthritis, menopause, and
aging.
(24–27) The mechanism of TNF-a as a mediator of bone
resorption has been studied in detail, including activation of
signaling pathways via NF-kB, MAPK, reactive oxygen species
(ROS), and NFatC1 and the effect of these signals on steps in the
oseoclast differentiation pathway.
(28–30) Less is known regarding
the inflammatory effects on OB function. A number of experi-
mental models have been used to show an inhibitory role for
TNF-a on OB differentiation and bone formation. These include
TNF-a-expressing arthritic mice, alcohol suppression of bone
formation, and estrogen deficiency.
(31–42) We reported pre-
viously that TNF-a is a potent inhibitor of the skeletal
transcription factors RUNX2 and Osx.
(16,19) TNF-a inhibits RUNX2
transcription by 50% and also stimulates a smurf1-mediated
ubiquitination/degradation of RUNX2, leading to a 90% reduc-
tion in RUNX2 protein in vitro and in vivo.
(43) TNF-a inhibits 90%
of Osx transcription in a MAPK/ERK1/2-dependent process. Low
concentrations of TNF-a also have been shown to inhibit the
osteoblast-specific markers alkaline phosphatase, bone sialo-
protein, and osteocalcin, as well as formation of mineralized
matrix, at doses 100-fold lower than observed in the rheumatoid
joint space, suggesting that OB precursors may be particularly
sensitive to inhibition by TNF-a.
(15,16,18) These actions of TNF-a
impair the recruitment of new OBs to eroded areas and suppress
healing of damaged bone in inflammatory disease.
We recently evaluated the structure of the Osx promoter to
identify the mechanism of TNF-a inhibition.
(19) Since regulation
of Osx by TNF-a is entirely transcriptional, we took advantage
of a defined TNF-a suppressor element in the Osx promoter
to identify bound nuclear proteins that could be molecular
mediators of inflammation and regulators of OB differentiation.
Here we report the results of these studies and the finding that
Prx1, a developmental regulator thought to be silenced after
embryogenesis, is reactivated by TNF-a to mediate inhibition of
osteoblastogenesis.
Materials and Methods
Reagents
MC3T3-E1 (clone 14) mouse preosteoblast cells were obtained
from Dr Renny Franceschi (University of Michigan, Ann Arbor, MI,
USA), and C3H10T1/2 cells were obtained from ATCC (Manassas,
VA, USA). The sources of reagents were as follows: human TNF-a,
PeproTech (Rocky Hill, NJ, USA); minimal essential medium
(MEM) and a-MEM, Gibco/Invitrogen (Grand Island, NY, USA);
heat-inactivated fetal bovine serum (FBS), HyClone (Logan, UT,
USA); and trypsin/versene, phosphate-buffered saline (PBS,
without Ca
2þ and Mg
2þ), and the Amaxa Nucleofector device
and reagents, Lonza (Walkersville, MD, USA). siRNA to Prx1, Prx2,
and negative-control siRNA were from Ambion/Applied Biosys-
tems (Austin, TX, USA), and siRNA transfection reagent was from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Superfect
transfection reagent, RNeasy Micro Kit, and Taq PCR Core Kit
were from Qiagen (Valencia, CA, USA). Oligonucleotides and
primers were purchased from Eurofins MWG Operon (Huntsville,
AL, USA). Real-time PCR was performed on the Bio-Rad MyiQ
using the iScript cDNA Synthesis Kit andiQ SYBRGreenSupermix
(Hercules, CA, USA). Other reagents were obtained from Sigma-
Aldrich (St Louis, MO, USA). The  1269/þ91 Osx promoter-
luciferase reporter (Osx–Luc) and deletion mutants were describ-
ed previously.
(19) The Dual Luciferase Assay System, TNF T7
Coupled Reticulocyte Lysate System, and pRL-TK control vector
were purchased from Promega Corporation (Madison, WI, USA).
Prx expression vectors were reported previously.
(44) The Chro-
matin Immunoprecipitation (ChIP) Assay Kit was from Upstate
Biotechnology/Millipore (Billerica, MA, USA). The p3xFLAG-CMV-
14 vector (C-terminal 3xFLAG) was purchased from Sigma-
Aldrich. Antibodies used for the ChIP assays were obtained from
Santa Cruz Biotechnology. The RUNX2 promoter was obtained
from Drs Jane Lian and Gary Stein (University of Massachusetts,
Worcester, MA, USA) and described previously.
(16,45) A rabbit
antibody to Prx1 was raised to a 50-mer murine peptide in the
laboratory of MJK and purified in the laboratory of MSN using
sepharose chromatography,
(46) The antibody bound Prx1a and
Prx1b but did not bind Prx2, as revealed by Western blot analysis
of recombinant proteins. Blocker bovine serum albumin (BSA) in
PBS (10 ) and the Fluorescein Isothiocyanate (FITC) Antibody
Labeling Kit were from Pierce/Thermo Scientific, Inc. (Rockford,
IL, USA). A second antibody to Prx1 was purchased from OriGene
Technologies (Rockville, MD, USA), and a Prx2-specific antibody
was purchased from Santa Cruz Biotechnology. Confocal micros-
copy was performed using a Fluoview 1000 microscope
(Olympus Corporation, Center Valley, PA, USA).
Nuclear pull-down
The oligo precipitation protocol was performed as described
previously with minor modifications.
(47) C3H10T1/2 cells were
treated with TNF-a (10ng/mL) or control medium for 18hours.
Cells were harvested in PBS and pelleted, and cytoplasmic and
nuclear fractions were isolated.
(47) Nuclear lysate (250mg) from
each sample was precleared with 75mL of Dynal magnetic beads
(Life Technologies, Carlsbad, CA, USA) and gel-shift binding
buffer (Promega) for 30minutes at room temperature. The Dynal
MPC-S Magnetic Particle Concentrator was used to remove the
beads. To bind the oligo to the beads, 100mL of Dynal beads and
Osx oligo (biotin-5’-TTGGATCTGAGTGGGAACAAGAGTGAGCTG-
3’ and 5’-CAGCTCACTCTTGTTCCCACTCAGATCCAA-3’) were incu-
bated at room temperature with gentle agitation for 30minutes
in PBS, followed by washing. Lysates from TNF-a and control
samples were added to the oligo-labeled beads with gel-shift
binding buffer (Promega) and incubated at room temperature
for 45minutes with gentle agitation. Beads were washed three
times with binding buffer with increasing KCl concentrations
(100, 250, and 500mM) using the magnetic concentrator. The
bound proteins were eluted from beads by adding 50mLo f
10mM dithreothreitol (DTT) in 50mM NH4HCO3 solution and
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twice, and the supernatants were combined and lyophilized. The
samples were reconstituted in 25mL of 20% acetonitrile in
50mM NH4HCO
3  containing 0.4mg of trypsin and incubated
overnight at 378C. Digests were lyophilized and desalted using
PepClean C-18 spin columns (Pierce) and resuspended in 0.1%
trifluoroaceticacid(TFA)priortomassspectrographic(MS)analysis.
Liquid chromatography mass spectrometry
Tandem mass spectrometry and bioinformatic analyses–liquid
chromatography (LC) were performed using a Dionex UltiMate
3000 LC system (Dionex Corporation, Sunnyvale, CA, USA)
coupled online with a linear-ion-trap (LIT) mass spectrometer
(MS) (LTQ-XL, ThermoFisher Scientific, Inc., Waltham, MA, USA).
Separations of each digest were performed on a 75-mm-inner-
diameter 360-mm-outer-diameter 10-cm-long fused silica
capillary column (Polymicro Technologies, Phoenix, AZ, USA),
with 5-mm, 300-A ˚ pore-size Jupiter C-18 stationary phase
(Phenomenex, Torrance, CA, USA) with an integrated electro-
spray ionization (ESI) emitter tip. After injecting 5mL of sample,
the column was washed with 98% mobile phase A (0.1% formic
acid in water) for 20minutes, and peptides were eluted by
development of a linear gradient of 2% mobile phase B (0.1%
formic acid in acetonitrile) to 42% mobile phase B in 140minutes
and then to 98% mobile phase B in an additional 10minutes, all
at a constant flow rate of 250nL/minute. The column was
washed for 20minutes with 98% mobile phase B and
equilibrated with 98% mobile phase A prior to subsequent
sample loading.
The MS was operated in a data-dependent MS/MS mode in
which each full MS scan (precursor ion-selection scan range of
m/z 350 to 1800) was followed by seven MS/MS scans, where the
seven most abundant peptide molecular ions were selected for
tandem MS using a relative collision-induced dissociation (CID)
energy of 35%. Dynamic exclusion was used to minimize
redundant selection of peptides for CID.
Tandem mass spectra were searched against the UniProt-
derived Mus musculus proteome database (www.expasy.org)
usingSEQUEST(ThermoFisherScientific,Inc.,Waltham,MA,USA).
Peptideswere considered legitimately identified if they achieved
a specific charge state and proteolytic cleavage–dependent
cross-correlation (Xcorr) scores of 1.9 for [MþH]
þ1, 2.2 for
[Mþ2H]
þ2, and 3.1 for [Mþ3H]
þ3 and a minimum delta
correlation score (DCn) of 0.08. These stringent filters resulted in
afalsediscoveryrateoflessthan 1%,asdeterminedbysearching
a reversed human proteome database, as described pre-
viously.
(48)
Cell culture
MC3T3-E1 clone 14 (MC3T3) or C3H10T1/2 cells were plated at
5 10
4/mL per well in 12-well plates (Costar, Lowell, MA, USA) in
MEM and 10% FBS, as described previously.
(16) TNF-a was added
on day 1 in the doses indicated for each experiment. Primary
marrow stromal cultures (MSCs) were prepared as described
using young-adult C57BL/6 male mice.
(18)
RNA harvest and quantitative RT-PCR
RNA was prepared using the RNeasy Micro Kit on the days
indicated for each experiment. Osx and RUNX2 promoter-
luciferasereportersweredescribedpreviously.
(16,19)Quantitation
of mRNA in total cell RNA was done in duplicate or triplicate
using the primers shown in Table 1.
Transfection and reporter assays
For reporter assays, cells were transfected with a mixture of
Superfect transfection reagent, medium, promoter reporter, and
pRL-TK control vector. Cells were harvested 48hours after
transfection andassayedusingtheDualLuciferase AssaySystem.
FireflyluciferasevalueswerenormalizedtoRenillaluciferasedata
to correct for transfection efficiency. For transfection of expres-
sion vectors, the same technique was used with exclusion of
Renillaluciferasevector. AdditionofsiRNAorrandomized control
was done 48hours prior to treatment with TNF-a using siRNA
transfection reagent. The medium was changed every 48 to
72hours.
In vitro translation
In vitro transcription/translation was done using the TNT T7
Coupled Reticulocyte Lysate System according to the manu-
facturer’s instructions.
Electrophoretic mobility shift assay
Electrophoretic mobility shifts (EMSAs) were done as described
previously.
(16,49) Probe sequences used for the TNF-a-responsive
site and homeodomain-binding site of the murine Osx promoter
are shown in the figures.
Table 1. PCR Primers
Gene Forward primer (5’!3’) Reverse primer (5’!3’)
28S rRNA TTGAAAATCCGGGGGAGAG ACATTGTTCCAACATGCCAG
Osx CCTCTCGACCCGACTGCAGATC AGCTGCAAGCTCTCTGTAACCATGAC
AP TTGTGCGAGAGAAAGAGAGAGA GTTTCAGGGCATTTTTCAAGGT
RUNX2 GAATGGCAGCACGCTATTAAATCC GCCGCTAGAATTCAAAACAGTTGG
BSP AACGCCACACTTTCCACACTCT CGTCGCTTTCCTTCACTTTTG
OC CTGACAAAGCCTTCATGTCCAA GCGCCGGAGTCTGTTCACTA
Prx1 CCCGGATGCTTTTGTTCGAGA CATGTGGCAGAATAAGTAGCCAT
Prx1a CATCGTACCTCGTCCTGCTC AGTCTCAGGTTGGCAATGCT
Prx1b CATCGTACCTCGTCCTGCTC GCCCCTCGTGTAAACAACAT
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ChIP assay was performed using the ChIP Assay Kit according
to the manufacturer’s instructions. Prx1 was cloned into the
p3xFLAG-CMV-14 vector to create FLAG-Prx1 for use in the pull-
down reactions. Antibodies used for ChIP assays were anti-HCC1,
HSP70, Radixin, NF-kB p65, VDR, Moesin, TIF1a, FLAG, and
normal mouse IgG. C3H10T1/2 cells were transfected with the
Prx1-FLAG expression vector, treated with TNF-a (10ng/mL), or
control medium, and ChIP assay was done 24hours later using
5 10
6 C3H10T1/2 cells for each pull-down reaction. Detection
of the antibody pull-down DNA complex of interest was done by
PCR using 10mL of DNA per sample and the Taq PCR Core Kit
at 40 cycles of 958C, 30seconds; 608C, 30seconds; and 728C,
1 minute. Primers spanned the TNF-a response region of the Osx
gene and upstream or downstream control sequences. Primer
sequences were TNF-a response region (forward) 5’-GACTC
AGAAG GAATG ATAGA GGCT-3’ and (reverse) 5’-AGTTA CAATC
TAGAG GCAGC CT-3’, upstream primers (forward) 5’-GTGTA
TGTCA GTGTG TTCCA GTCTT-3’ and (reverse) 5’-GCTGG GAGGG
ATCTG CTCCT CTCTC-3’, and downstream primers (forward) 5’-
GGGTT AAGGG GAGCA AAGTC AGAT-3’ and (reverse) 5’-CTGGG
GAAAG GAGGC ACAAA GAAG-3’. PCR products were resolved
by agarose-gel electrophoresis and visualized with ethidium
bromide.
Fluorescent immunohistochemistry
MC3T3 cells were treated with control medium or TNF-a (10ng/
mL), as indicated in the figures. Cells were fixed in 95% ethanol
for 10minutes, followed by rinsing three times in PBS for
5minutes each. Cells were blocked using 3% bovine serum
albumin (BSA) in PBS (prepared from Blocker BSA in PBS) for
1 hour at room temperature. Prx1 antibody labeled with fluore-
scein isothiocyanate (FITC) was prepared according to kit in-
structions. Endogenous Prx1 was detected by incubating fixed
cells with FITC–anti–Prx1 (1:50 in PBS) at 48C overnight, followed
by rinsing two times in PBS for 5minutes each. Nuclei were
counterstained with 4,6-diamidino-2-phenylindole (DAPI), and
cells were examined using a confocal microscope with a  40
objective under oil immersion. Wavelengths used were 488
(FITC) and 350nm (DAPI).
TgTNF mice and histology
Use of mice was approved by the institutional animal use
committee of the VA Medical Center. Female TgTNF mice
[B6.Cg(SJL)-Tg(TNF) N21þ?] were purchased from Taconic
(Hudson, NY, USA). Tibias were harvested from 12-week-old
mice expressing 3 to 5pg/mL of human TNF-a or from wild-type
littermates. Bones were cleaned, fixed in paraformaldehyde, and
embedded in paraffin, and 5-mm cuts of the proximal tibia were
made to include a portion of the cartilage, trabecular bone, and
periosteal bone. Sections were processed for immunohistology
using the antibody raised in our laboratory and described earlier.
Statistical analysis
ANOVA was used to determine a statistical difference between
multiple groups. Multiple comparisons between individual
groups were done by the method of Tukey. Comparison
between any one group and a common control was done by the
method of Dunnett using Prism software (Irvine, CA, USA).
Results
Identification of proteins binding the TNF-suppressor
element of the Osx promoter
The TNF-responsive sequence from the Osx promoter, TTGGAT-
CTGAGTGGGAACAAGAGTGAGCTG, was bound to sepharose
beads and used as bait to identify the interacting nuclear protein
complex in MC3T3 cells. MS identified fragments from 655
individual proteins. Since the probability of a true positive TNF-
regulated protein increases with the number of identified
fragments of that protein, further analysis was restricted to 62
proteins for which 2 or more fragments were detected and TNF
modified detection of the protein. Table 2 shows these proteins
arranged by known function. As expected, most were nuclear
Table 2. Nuclear Factors Identified by Mass Spectroscopy at the Osx TNF-a Element With Known Differentiation Regulatory,
Transcriptional Regulatory, or TNF-a-Responsive Functions
Factor Known functions
Accession
number
TNF-induced
TIF1b Tripartite motif protein 28 Transcriptional coactivator of nuclear receptors Q62318
HSC71 Heat shock cognate 71-kDa protein TNF-induced chaperone protein P63017
Radixin (ESP-10) Component of ‘‘merlin’’ complex; regulation of
NF-kB-induced transcription, actin-modifying protein
P26043
Ewing sarcoma homologue Associates with TFIID Q5SUS9
PRX1 Paired mesoderm homeobox protein 1 Early limb bud, bone, and vascular differentiation factor P63013
TNF-displaced
CRP-2 Cysteine-rich protein 2 (DLP-2) Mesenchyme smooth muscle differentiation factor;
LIM protein expressed e9.5-e16.5 in smooth muscle
P97315
HCC-1 DNA-binding factor, inhibits cell growth Q9D1J3
Moesin Membrane-organizing extension spike protein Component of ‘‘merlin’’ complex; regulation of
NF-kB-induced transcription, actin-modifying protein
P26041
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ciated with nuclear structure and its organization around the
transcriptional apparatus. Eight proteins were studied further
because they were transcription-modifying nuclear proteins,
regulators of cell differentiation, or known TNF-regulated
proteins. Analysis focused on these as potential direct regulators
of the Osx promoter. Three of the proteins were TNF-displaced.
These included cysteine-rich protein-2 (CRP-2, DLP-2), known to
regulate differentiation of smooth muscle from mesenchyme;
HCC-1, a DNA-binding factor that inhibits cell growth; and
moesin, a member of the ‘‘merlin’’ regulatory complex. Five
proteins had increased binding after TNF-a treatment. These
included tripartite motif protein 28 (TIF1b), a known transcrip-
tionalcoactivator ofnuclearreceptors; heatshock cognate71-kD
protein, a chaperone previously identified in an array of TNF-
induced proteins; radixin (ESP-10), another component of the
‘‘merlin’’ complex of ezrin-moesin-radixin described to block
NF-kB-induced transcription; Ewing sarcoma homologue; and
paired mesoderm homeobox protein 1 (Prx1, Prrx-1, MHox).
Prx1 is a factor required for early limb bud formation,
skeletal patterning, and early pulmonary and cardiovascular
differentiation.
ChIP assays were done to confirm binding of the selected
proteins to the TNF-a repressor element of the Osx promoter.
C3H10T1/2 cells were used for ChIP assays after treatment
with TNF-a (10ng/mL) or control medium. These experiments
confirmed binding of moesin, TIF1b, and Prx1 to the region
containing the TNF-a element. Figure 1 shows a map of the Osx
promoter and illustrates the location of TNF-a element–flanking
primers used for ChIP assay. The experiment shown in Fig. 1A did
not support binding of HCC1 or radixin with the available
antibodies. As expected, the negative controls IgG, p65, and VDR
were not bound. Figure 1B shows that TNF-a stimulated the
binding of Prx1 (arrow) and confirmed the constitutive binding
of moesin and TIF1b. Figure 1C shows that upstream and
downstream primers, distal to the TNF/MAPK element, revealed
only a faint signal or none, supporting the specificity of Prx1
bound to the TNF-a site.
TNF-a regulates Prx expression
Since TNF-a stimulated binding of Prx1, a factor previously
described as a regulator of skeletogenesis, we focused on this
factor as a potential mediator of TNF-a suppression of Osx
transcription. Figure 2 shows the effect of TNF-a treatment on
the expression of Prx1a and Prx1b isoforms, as well as the closely
related Prx2 gene. The comparative structures of Prx1 isoforms
and Prx2 are shown in Fig. 2A, as adapted from Norris and
colleagues.
(44) These proteins share a common Prx region and
homeodomain sequence. Prx1a and Prx2 also share a similar
transcriptional activation domain (OAR). TNF-a robustly stimu-
latedtheexpressionofPrx1aandPrx1b14-fold(Fig.2B,C).TNF-a
also modestly stimulated Prx2 2.8-fold (Fig. 2D).
Fig. 1. ProteinbindingtotheTNF-arepressorelementoftheOsxpromoterisconfirmedbyChIPassays.C3H10T1/2cellstreatedwithTNF-a(10ng/mL)or
control medium for 24hours were used for ChIP assays. At the top is a map of the Osx promoter, including the TNF-a response element region. Primer
sequences are listed in Table 1. (A) ChIP assays used antibodies against normal mouse IgG (as control), HCC1, HSP70, radixin, NF-kB p65, VDR, moesin, or
TIF1. PCR reactions used the primer pair flanking the TNF-a response element region indicated on the map. Molecular-weight markers are on each end.
(B) ChIP assays used antibodies againstnormal mouseIgG (as control), moesin, TIF1, or Prx1. Other controls were doneto test the washstep and theeffect
ofnoantibody,aswellas toverifythepresenceoftherelevantsequenceinthestartingDNAsample(input).Theprimersusedwerethesameas inpanelA.
(C) PCR reactions used the same DNA as in panels A and B and primers that were upstream or downstream of the TNF-a response element.
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lated the accumulation of Prx1 protein in the cytoplasm and
nucleus within 15minutes, as shown by fluorescent immuno-
histology (Fig. 3A). This nuclear localization was sustained
through a subsequent 18hours of culture (ON¼overnight).
Figure 3B is a closer view from another experiment showing
cytoplasmic and punctuate nuclear accumulation after TNF-a
treatment. To determine if Prx1 is expressed in vivo, we used
transgenic TNF mice (TgTNF) that develop inflammatory arthritis
and systemic bone loss in response to global expression of
human TNF. Immunostaining of bones obtained from 12-week-
old mice revealed Prx1 staining in periosteal lining cells that was
only weakly detected in bones of wild-type littermates (Fig. 3C).
Additional sections revealed staining in trabecular lining cells
and in macrophages and megakaryocytes in bone marrow (not
shown).
Prx1 mediates TNF-a inhibition of Osx transcription
We tested the role of Prx1 as a mediator of TNF-a inhibition of
Osx by silencing Prx1 with a short interfering RNA (si-Prx1) that
inhibited expression of all Prx1 isoforms. Figure 4A shows that
TNF-a stimulation of Prx1 was blocked by the si-Prx1. si-Prx1 had
no effect on Prx2 expression (not shown). Figure 4B shows that
the si-Prx1 completely abrogated TNF-a inhibition of Osx mRNA.
Fig. 2. Prxexpressionis regulatedby TNF-a.(A) GenestructuresofthePrx1isoformsandPrx2. (B–D) RNAwaspreparedfromC3H10T1/2 cellstreatedwith
control medium or TNF-a (10ng/mL) for 24hours. Quantitative RT-PCR using primer pairs specific for Prx1a (B), Prx1b (C), or Prx2 (D) (Table 1) was
performed.
Fig. 3. TNF-a stimulates expression of Prx1 in vitro and in vivo. (A) MC3T3 cells treated with control medium or TNF-a (10ng/mL) for the indicated times
and labeled with fluorescein-conjugated anti-Prx1 antibody (FITC-Prx-1). Increased signal intensity is seen within 15minutes and is sustained. Nuclei were
counterstained withDAPI, andcellswere examinedby confocal microscopywith a  40oil-immersionobjective. (B) As in panelA, showinga closerviewof
increased cytoplasmic and punctuate nuclear accumulation after TNF-a treatment from another experiment. (C) Immunostaining shows Prx detection in
tibial periosteal lining cells from TgTNF arthritic mice but little or no signal in wild-type littermates. Shown are TgTNF, wild-type, control antibody, and
hematoxylin and eosine (H&E)–stained sections from the proximal tibia. Bones were obtained from 8-week-old mice.
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for RUNX2 mRNA (Fig. 4C).
Prx1b and Prx2 bind the TNF-a element and an upstream
homeobox site
Analysis of the Osx promoter sequence revealed a homologous
homeobox-binding site just upstream of the 18-bp TNF-a
response element, contiguous with a previously described
RUNX2-binding site.
(50) Therefore, we evaluated whether TNF
stimulated binding of Prx1 to the Osx promoter at both the TNF-
a response element and the upstream homeobox-RUNX2 site.
Nuclear extract from C3H10T1/2 cells was isolated from control
and TNF-a-treated cells and incubated with
32P-labeled TNF-a
response element or homeobox probes. Figure 5A shows that
two bands were observed at the TNF-a element (A, control, þNE)
that increased in intensity after 18hours of TNF-a treatment (A,
TNF, þNE). This complex contained Prx1 because the top band
was supershifted by our Prx1 antibody (aPRX1#2) but not by a
commercial antibody (aPRX#1) or a Prx2 antibody (aPRX2).
Specificity of binding also was demonstrated by competition
with 100X cold TNF element probe (TRE) but not by a control
DNA sequence. Figure 5B shows that the homeobox probe also
bound a complex that was supershifted by both Prx1 antibodies
butnotbythePrx2antibody.Thisbindingwasspecificbecauseit
was competed by 100X unlabeled homeobox probe (HBX).
In contrast to the effect of TNF-a on binding of Prx1 to the TNF-a
element, binding to the homeobox site was constitutive.
Binding to the promoter was evaluated further with recom-
binant Prx1a and Prx1b. Proteins were synthesized by in vitro
transcription/translation using isoform-specific cDNA templates
driven by the bacterial T7 promoter. These protein products or a
control reaction supernatant was tested for binding to the TNF-a
element of the Osx promoter. Figure 6A shows an EMSA done
with the
32P-labeled TNF-a element, the recombinant proteins,
and nuclear extract from TNF-a-treated C3H10T1/2 pluripotent
mesenchymal cells. Prx1b and Prx2, but not Prx1a or the control
reaction, readily bound the probe under these conditions.
Binding of recombinant Prx1b required the inclusion of nuclear
extractintheEMSAreaction,asshowninFig.6B.Figure6Cshows
thatPrx1bwasabletobindthehomeoboxsiteinthepresenceor
absence of nuclear extract.
Fig. 4. TNF-a inhibition of Osx mRNA is mediated by Prx1. C3H10T1/2
cells were transfected with control or Prx1 siRNA, followed by treatment
with control medium or TNF-a (10ng/mL) for 24hours. RNA was pre-
pared and analyzed by quantitative RT-PCR using Prx1-, Osx-, or Runx2-
specific primer pairs, as shown in Table 1. (A) Prx1. (B) Osx. (C) Runx2.
Fig. 5. Prx1 binds the Osx promoter. Nuclear extract was prepared from
C3H10T1/2 cells treated with TNF-a (10ng/mL) for 18hours. EMSA was
carried out using
32P-labeled dsDNA TNF-a response element or homeo-
box-bindingsiteoligos,alongwith theindicatedcombinationsofnuclear
extract, antibodies, and cold probes. (A) EMSA showing labeled TNF-a
responseelement–bindingnuclearproteinfromcontrolorTNF-a-treated
C3H10T1/2 cells. The arrow on the left of the gel identifies the Prx1 band.
TNF-a increased binding to the probe (control, þNE versus TNF, þNE).
The binding is supershifted by a Prx1 antibody (aPrx#2) but not by a Prx2
antibody(aPrx2)oracommercialPrx1antibody(aPrx1#1)andcompeted
by 100X unlabeled probe (TRE) but not by 100X unlabeled control probe.
(B) EMSA using a probe from a homeobox homologous site upstream of
theTNF-asitethat includesacontiguousRUNX2-bindingsite.Thearrows
on the left of the gel identify Prx1 bands. The binding is reduced or
supershifted by two different Prx1 antibodies (aPrx1, #1 or #2) and
competed by 100X cold probe. TNF-a treatment did not change the
binding to this site.
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osteoblast differentiation
We tested whether Prx expression would inhibit the expression
of the genes required for OB differentiation or the expression of
phenotypic markers of the mature OB. MC3T3 cells or primary
MSCs were transiently transfected with Prx1a, Prx1b, or Prx2
expressionvectors.Figure7AshowsthatoverexpressionofPrx1b
and Prx2, but not Prx1a, inhibited Osx mRNA levels by 50%,
similartotheactionofTNF-a.
(19)Interestingly, althoughsilencing
of Prx1 did not affect basal RUNX2 mRNA, overexpression of
Prx1bandPrx2inhibitedRUNX2mRNA(Fig.7B).ExpressionofPrx
proteins also reduced transcription of both Osx- and RUNX2-
luciferase reporters, with Prx2 showing the highest potency (not
shown). Transient expression of Prx1b and Prx2 also inhibited
terminal differentiation of MC3T3 cells, as seen by the reduction
inmineralizedalizarinred–stainednodulesinFig.7C.Figure8A,B
shows a similar experiment in primary MSCs. Again, Prx1b and
Prx2, but not Prx1a, inhibited Osx and RUNX2 (Fig. 8A, B).
Discussion
Our experiments were designed to reveal early steps in the
molecular action of TNF-a that inhibit OB differentiation. A
critical requirement in OB differentiation is the expression of Osx
because lack of this protein during development results in a
cartilaginous skeleton.
(10) Since TNF-a inhibits Osx expression by
a predominantly transcriptional mechanism, we focused on
identification of TNF-a-induced proteins bound to the core TNF-
ainhibitoryelementontheOsxpromoter.Ourpull-downstudies
identified a number of proteins that were bound to this DNA
element in a TNF-a-dependent manner. One of these, Prx1, was
regulated by TNF-a and confirmed in ChIP assay. We have not
excluded a role for other proteins, including moesin and TIF1b,
which could cooperate with Prx1; however, Prx1 was induced by
TNF-a treatment, and functional studies revealed a specific role
for this protein.
Fig. 6. Delineation of Prx isoforms binding the Osx promoter TNF-a
response element. Recombinant Prx1a, Prx1b, and Prx2 proteins were
synthesized by in vitro transcription/translation. Nuclear extract was
prepared from C3H10T1/2 cells treated with TNF-a (10ng/mL) for
24hours. EMSA was carried out using
32P-labeled dsDNA TNF-a response
element or homeobox-binding site oligos, along with the indicated
combinations of recombinant proteins and nuclear extract. Controls
were prepared without recombinant protein. (A) Recombinant Prx1b
and Prx2, but not Prx1a, bind the TNF-a response element in the
presence of nuclear extract. (B) Recombinant Prx1b fails to bind the
TNF-a response element in the absence of nuclear extract. (C) Homeo-
box-binding site (upstream of the TNF-a element). Recombinant Prx1b
and Prx2 bind the upstream homeobox element with or without nuclear
extract. Arrows indicate the locations of protein-DNA complexes.
Fig. 7. Osteoblast differentiation and Osx and RUNX2 expression are
inhibited by Prx1b and Prx2 in preosteoblasts. MC3T3 cells were tran-
sientlytransfectedwithPrx1a,Prx1b,orPrx2expressionvectorsusingthe
Amaxa nucleofection system. RNA was prepared 48hours after transfec-
tion. (A) Quantitative RT-PCR using primers specific for Osx.( B) Quanti-
tativeRT-PCRusingprimersspecificforRUNX2.(C)MC3T3cellstransiently
transfected with Prx1a, Prx1b, or Prx2 expression vectors using the
Amaxa nucleofection system. Transfected cells were cultured in miner-
alization medium for 14 days and then stained with alizarin red.
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protein with a lesser stimulation of the closely related Prx2
in cultured primitive mesenchymal cells. In addition, TNF-a
stimulated rapid nuclear localization of Prx protein and positive
immunostaining in bone lining cells that are a source of
preosteoblasts. Functional studies support a role for Prx as a
mediator of TNF-a. First, silencing of Prx1 using a Prx1-specific si-
RNA abrogated TNF-a inhibition of Osx expression. Second,
overexpression of Prx1b and Prx2, but not Prx1a, inhibited Osx
and RUNX2 mRNA. Finally, Prx1b and Prx2 transient expression
inhibitedtheosteoblasticdifferentiationofpreosteoblasts.These
results suggest that Prx1b and Prx2 are TNF-a-induced inhibitors
of Osx and OB differentiation.
Prx genes have long been known to have a role in embryonic
limb bud formation and skeletal development.
(51–54) Prx1 is
expressed in developing mouse mesenchyme until day e11.5, a
time spanning the onset of skeletal development, after which
levels are reduced. Prx1 also indirectly modulates sonic hedge-
hog expression, a factor important for the balance of prolife-
rationversusdifferentiationofprecursorcells.
(55)Thefindingthat
Prx1 mediates TNF-a inhibition ofOB differentiation isconsistent
with previous reports on the effect of global deletion of Prx1
or Prx2. An abnormal skeletal phenotype is observed in Prx1
 / ,
but not Prx2
 / , mice, characterized by defects in mandibular
development, short, thickened limbs, and normal growth
plates.
(53) Although Prx2 knockouts are indistinguishable from
wild-type mice, Prx1
 / /Prx2
 /  double knockouts have a more
severephenotype,includingdefectsofthecraniofacial,limb,and
vertebral skeletons. These findings indicate a weak functional
redundancy of Prx1 and Prx2. Although Prx genes were first
identifiedas limb bud inducers, sustained expressioncould serve
to limit premature bone maturation to ensure correct skeletal
patterning. Thus, silencing of Prx expression may be required to
allow skeletal maturation to proceed coordinately with limb
development. This hypothesis is consistent with in vitro studies
of mesenchymal differentiation in micromass cultures showing
Prx1b inhibition of chondrogenic nodule formation.
(56)
We found that TNF-a stimulated the expression of Prx1. TNF-a
induces Prx1 more robustly than Prx2, suggesting that it is the
more important mediator of inflammation. Information regard-
ing the role of Prx1 in bone is limited because global knockout is
lethal owing to abnormal cardiac and pulmonary vascular
development. Although the specific role of Prx1 in OB differen-
tiationhasyettobeunveiled,ourresultsindicatethatTNF-a,and
perhaps other inflammatory stimuli, could reactivate Prx expres-
sion in inflammatory arthritis, aging, and menopause. This re-
activation of Prx1 then would decrease Osx and RUNX2, reduce
OB differentiation, and impair healing of resorbed bone.
Our studies also suggest that Prx1b is the isoform that
mediates TNF-a inhibition of Osx and OB differentiation. We
found that recombinant Prx1b, but not Prx1a, binds the TNF-a
element of the Osx promoter in EMSA. Similarly, expression of
Prx1b, but not Prx1a, inhibits OB differentiation in vitro. Prx
isoforms have been shown previously to differentially regulate
transcription. Transcriptional potency has been attributed to a
conserved Prx domain among homeobox-containing genes,
whereas an OAR (aristaless domain, conserved among paired-
type homeodomain proteins), present in Prx1a, but not Prx1b,
has been found to be an inhibitor of tenacsin gene transcrip-
tion.
(44)TheOARisunlikelytoaccountforthedifferencebetween
Prx1a and Prx1b in our studies because it is conserved in Prx2,
which functions similarly to Prx1b as an OB inhibitor. EMSA
studies showed that recombinant Prx1b bound the TNF-a
element protein complex on the Osx promoter and that this
binding greatly increased after TNF-a treatment. We predict that
this binding could be stabilized by the upstream homeobox site,
which also was found to bind Prx constitutively. ChIP assay is not
sensitive enough to precisely localize the binding of Prx1
because the primers span too large a region to detect the PCR
signal. Nevertheless, the TNF-a element is sufficient for TNF-a
action because point mutations of this sequence abolish TNF-a
inhibition of Osx transcription, and transfer of the TNF-a element
to a heterologous promoter confers TNF-a responsiveness in the
absence of the upstream homeodomain sequence.
(19)
Our prior studies of the Osx promoter revealed a MAPK/MEK/
ERK1/2-dependent mechanism for TNF-a action. Although
additional studies will be required to determine if TNF-a activa-
tionofPrx1b involvesMAPK, experiments werereported toshow
MAPK/MEK/ERK1/2 and also AKT dependence for Prx action in
amphibian regenerating limbs.
(57)
TNF-a has a major role in the pathophysiology of skeletal
disorders, including inflammatory arthritis, menopausal bone
loss, and aging. These disorders share a reduced capacity of OBs
Fig. 8. Prx1b and Prx2 inhibit osteoblast differentiation and Osx and
RUNX2 expression in primary MSC cultures. Mouse primary MSC suspen-
sions were prepared at 5 10
6 cells/mL in a-MEM and 10% FBS and
transientlytransfectedwithPrx1a,Prx1b,orPrx2expressionvectorsusing
the Amaxanucleofection system. Transfected cells were platedin 12-well
plates (1mL/well) and supplemented with 50&g/mL of L-ascorbate and
5mMb-GP. RNA was prepared after 48hours, and quantitative RT-PCR
was performed. (A) Osx.( B) RUNX2.
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differentiation and function are likely reasons for this defect. We
and others established TNF-a as an inhibitor of early commit-
ment of OB precursors.
(13,14,16,17,56) In rheumatoid arthritis, OB
function is impaired, and continued periarticular bone destruc-
tion is not balanced by adequate bone formation, an effect
countered by anti-TNF-a therapy.
(17,58,59) In another model of
decreased bone formation owing to alcohol exposure, TNF-a is
responsible for inhibiting the recruitment of OBs needed for
skeletal renewal.
(34–38) Ovariectomy is associated with a rise in
the expression of inflammatory cytokines, including TNF-a,
accelerated bone resorption, and a blunted increase in bone
formation that is insufficient to prevent net bone loss. Finally,
recent work suggests that impaired fracture healing in aging
is due to reduced OB differentiation and function, a defect
corrected by inhibition of TNF-a.
(38) Thus in vitro and in vivo
skeletal models show that TNF-a suppresses OB differentiation
and bone formation, in addition to stimulation of osteoclastic
resorption. In summary, we have identified Prx1 as a molecular
mediator of TNF-a inhibition of OB differentiation through
suppressionofOsxandRUNX2expression.Furtherstudieswillbe
needed to evaluate the role of Prx1 in vivo.
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